Treace Medical Concepts (TMCI) Set to Announce Earnings on Friday

Treace Medical Concepts (NASDAQ:TMCI) is expected to post its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Treace Medical Concepts to announce earnings of ($0.26) per share and revenue of $47.80 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.

Treace Medical Concepts (NASDAQ:TMCI) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.06. Treace Medical Concepts had a negative net margin of 28.99% and a negative return on equity of 71.37%. The firm had revenue of $45.38 million for the quarter, compared to analysts’ expectations of $44.02 million. On average, analysts expect Treace Medical Concepts to post ($0.83) EPS for the current fiscal year and ($0.81) EPS for the next fiscal year.

Treace Medical Concepts Trading Up 0.2%

NASDAQ TMCI opened at $4.28 on Wednesday. Treace Medical Concepts has a 12 month low of $1.17 and a 12 month high of $6.58. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.90 and a quick ratio of 1.95. The company has a market capitalization of $278.37 million, a price-to-earnings ratio of -4.60 and a beta of 1.59. The company’s fifty day moving average price is $4.42 and its two-hundred day moving average price is $3.26.

Wall Street Analysts Forecast Growth

TMCI has been the subject of several research analyst reports. Weiss Ratings raised shares of Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Truist Financial increased their price target on shares of Treace Medical Concepts from $4.00 to $5.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $5.17.

Insider Activity at Treace Medical Concepts

In other news, CEO John Treace purchased 39,944 shares of the stock in a transaction dated Thursday, August 20th. The stock was acquired at an average cost of $4.44 per share, for a total transaction of $177,351.36. Following the acquisition, the chief executive officer owned 7,388,383 shares of the company’s stock, valued at $32,804,420.52. The trade was a 0.54% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders purchased 55,944 shares of company stock valued at $246,841. 23.42% of the stock is currently owned by company insiders.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of bunion deformities and other conditions affecting the foot and ankle. The company’s technologies are designed to address the underlying structural causes of bunions and support more stable correction than traditional surgical approaches.

Treace’s primary product is the Lapiplasty 3D Bunion Correction System, which is used by foot and ankle surgeons to correct bunions in three dimensions.